

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care.

Total revenues over \$1,827m in 2019
Market growth rate c.4%
Leading positions across key markets



Advanced Wound Care

Advanced wound care solutions for patients with hard to heal wounds caused by diabetes and other conditions



Ostomy Care

Chronic care products serving patients with ostomies arising from colorectal malignancies and inflammatory bowel diseases



Continence & Critical Care

Products serving patients with chronic urinary or fecal continence conditions. Plus devices and products used in ICU and hospital settings.



Infusion Care

Serves diabetes patients dependent on insulin delivery and sets for continuous infusion treatments for conditions such as Parkinson's disease

Our Strategic Pillars

Focus

On "must win" markets and categories

Innovate

in our work and trusted solutions

Simplify

our operations

Build

"mission-critical" capabilities

Execute

with excellence



Dr John McAdam
Chairman

- Successful business leader and Chairman
- Wealth of experience that includes Chairman of Rentokil Initial and United Utilities
- 20 years' service as a Board director, including Chair and CEO of companies undertaking transformation



Karim Bitar
CEO

- Previously CEO of Genus plc, a leading global agricultural biotechnology company
- Over 15 years' experience at Eli Lilly & Company
- Ex McKinsey & Company consultant who has worked across Asia and Europe in multinational corporations including Johnson & Johnson



Frank Schulkes
CFO

- Previously CFO of Wittur Group, a privately-held industrial company
- Spent 27 years in a variety of senior finance roles at GE Healthcare, a global medical technology, life sciences and services company

2019 financial highlights

Constant currency revenue growth 2.4%

Adj. EBIT margin of 19.4%

98% Adjusted cash conversion



Across the globe, there is a growing incidence of chronic conditions with patients living longer...

	Macro drivers			Industry drivers	Market size	Market growth
	Actual	Predicted				
Aging population Global 60yr+	0.9bn	2.1bn	>>	Pressure on healthcare costs	c\$7bn	4%
	2017	2050				
Increasing prevalence of chronic conditions Global diabetes	392m	489m	>>	Expanding access to healthcare	c\$2.5bn	4%
	2015	2025				
Patients live longer with chronic conditions Life expectancy of type 1 diabetes	53yr	69yr	>>	Consumer engagement in healthcare	c\$2bn	4%
	1950-64	1965-80				
				Increasing use of insulin pump devices	\$1bn	5+%